[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100592223":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":21,"collaborators":10,"id":25,"slug":26,"hasResults":27,"nctId":28,"briefTitle":29,"officialTitle":30,"acronym":31,"eligibilityCriteria":32,"healthyVolunteers":27,"sex":33,"minAge":34,"maxAge":10,"enrollmentInfo":35,"targetDuration":10,"studyType":38,"phases":10,"briefSummary":39,"conditions":40,"keywords":44,"overallStatus":46,"whyStopped":10,"lastUpdateSubmitDate":47,"lastUpdatePostDateStruct":48,"startDateStruct":51,"completionDateStruct":53,"leadSponsor":55,"locationsCount":10},{"fullName":5,"class":6},"Izmir Ataturk Training and Research Hospital","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"dmmr",null,[12],"Diagnostic Test: diagnostic test",{"label":14,"type":10,"description":14,"interventionNames":10},"mmr expression normal",[16],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"DIAGNOSTIC_TEST","diagnostic test","Group 1: MMR-Proficient Group Label: MMR-Proficient\n\nDescription: Patients with normal expression of MMR proteins on IHC analysis. No indication for further genetic testing.\n\nType: Observational Group\n\nGroup 2: dMMR Group Label: dMMR\n\nDescription: Patients with loss of MMR protein expression (MLH1, PMS2, MSH2, or MSH6) on IHC. These patients will undergo further molecular or genetic analysis to evaluate for Lynch syndrome.\n\nType: Observational Group",[9],{"type":22,"investigatorFullName":23,"investigatorTitle":24,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","SAADET KOCA","md ftbs phd-c","100592223","lynch-syndrome-in-colorectal-cancer-surgery-100592223",false,"NCT06990633","Lynch Syndrome in Colorectal Cancer Surgery","LYNX STUDY: Lynch Syndrome in Colorectal Cancer Surgery - A Multicentre, Prospective Cohort Study","LYNX","Inclusion Criteria:\n\nAge 18 years or older\n\nHistologically confirmed diagnosis of colorectal adenocarcinoma\n\nUndergoing surgical resection at one of the participating general surgery departments\n\nAvailability of formalin-fixed, paraffin-embedded (FFPE) tumor tissue for MMR analysis\n\nConsent to participate in the study and undergo genetic testing if indicated\n\nExclusion Criteria:\n\nAge below 18 years\n\nDiagnosis other than colorectal adenocarcinoma\n\nIncomplete or unavailable postoperative pathology results\n\nInadequate tissue samples for IHC analysis\n\nPatients who decline participation in the study at any point\n\nPatients who do not attend or refuse referral to genetic counseling after pathology results","ALL","18 Years",{"count":36,"type":37},180,"ESTIMATED","OBSERVATIONAL","Study Design (Material and Methods)\n\nThis is a multicentre, prospective cohort and audit study conducted in Türkiye. The study aims to evaluate the incidence of Lynch syndrome among patients who undergo surgery for colorectal cancer in participating general surgery departments.\n\nOver a 12-month period, patients undergoing surgery for histologically confirmed colorectal cancer at multiple tertiary hospitals across Türkiye will be enrolled. Postoperative pathological assessments will include immunohistochemical (IHC) analysis for mismatch repair (MMR) protein expression (MLH1, PMS2, MSH2, and MSH6).\n\nIn cases showing loss of MLH1 and PMS2 expression, BRAF mutation testing will be performed. If BRAF mutation is detected, MLH1 promoter methylation analysis will follow. A positive result in both tests will suggest a sporadic etiology, whereas the absence of both findings will lead to referral for germline genetic testing using next-generation sequencing (NGS) to investigate Lynch syndrome.\n\nFor patients with isolated MSH2 and\u002For MSH6 loss, direct referral to genetic testing will be carried out without BRAF or methylation testing.\n\nPatients with intact MMR expression will be recorded as the MMR-proficient control group. Comparative analysis will be conducted between dMMR and MMR-proficient patients, including demographic characteristics (age, sex, family history of cancer), tumor staging, anatomical location, and presence of metastases.\n\nThe primary outcome is to determine the incidence of Lynch syndrome among surgically treated colorectal cancer patients in Türkiye and to identify clinical and pathological correlations.",[41,42,43],"Colo-rectal Cancer","Hereditary Diseases","Lynch Syndrome",[45],"Lynch Syndrom, Colorectal Cancer","NOT_YET_RECRUITING","2025-05-17",{"date":49,"type":50},"2025-05-25","ACTUAL",{"date":52,"type":37},"2025-07-01",{"date":54,"type":37},"2026-08-01",{"name":5,"class":6}]